AstraZeneca Acquires Omniose to Strengthen Vaccine Pipeline - Global Banking & Finance Review
Article excerpt
Highlighted: the sentence this signal was extracted from
Nov 10 (Reuters) - AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday. ⢠"Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's senior vice president of infectious disease ⢠Despite a diverse drug portfolio, AstraZeneca's on-market vaccine offerings are limited, and its CEO is refocusing on growth, with over 180 pipeline projects underpinning long-term ambitions ⢠AstraZeneca discontinued its Covid-19 vaccine in 2024, but now offers Beyfortus for respiratory syncytial virus infections and FluMist for influenza ⢠It is also exploring the development of cancer vaccines (Reporting by Raechel Thankam Job in Bengaluru; Editing by Vijay Kishore)